|
Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified |
3 Months Ended | 9 Months Ended | 105 Months Ended | ||
|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
|
| Statements of Operations | |||||
| Grant revenue | $ 650 | ||||
| Operating expenses: | |||||
| Research and development | 3,932 | 2,220 | 8,275 | 9,033 | 79,682 |
| Acquired in-process research and development | 5,500 | ||||
| Selling, general and administrative | 3,655 | 3,525 | 8,963 | 8,332 | 43,862 |
| Total operating expenses | 7,587 | 5,745 | 17,238 | 17,365 | 129,044 |
| Loss from operations | (7,587) | (5,745) | (17,238) | (17,365) | (128,394) |
| Interest income | 2 | 2 | 10 | 17 | 679 |
| Interest expense | (226) | (446) | (713) | (1,293) | (10,115) |
| Change in fair value of warrants | (12,162) | (13,449) | |||
| Loss on debt extinguishment | (799) | ||||
| Loss before tax benefit | (7,811) | (6,189) | (30,103) | (18,641) | (152,078) |
| Income tax benefit | 839 | ||||
| Net loss | (7,811) | (6,189) | (30,103) | (18,641) | (151,239) |
| Series A Preferred Stock dividends | (314) | (13,564) | |||
| Net loss applicable to common stockholders | $ (7,811) | $ (6,189) | $ (30,417) | $ (18,641) | |
| Basic and diluted net loss per common share (in dollars per share) | $ (0.25) | $ (0.42) | $ (1.04) | $ (1.26) | |
| Weighted average basic and diluted common shares outstanding (in shares) | 31,468,063 | 14,752,214 | 29,360,455 | 14,740,578 | |